Diagnostic value of miRNA-25 for different cancers in Chinese population: a Meta-analysis
10.3760/cma.j.cn431274-20191105-01283
- VernacularTitle:miRNA-25对中国不同恶性肿瘤患者诊断价值的Meta分析
- Author:
Yuan ZHAO
1
;
Siming CHEN
;
Yilan JIANG
Author Information
1. 湖南省中医药研究院附属医院肿瘤科，长沙 410013
- From:
Journal of Chinese Physician
2020;22(4):569-574
- CountryChina
- Language:Chinese
-
Abstract:
Objective:Meta analysis was used to evaluate the diagnostic value of miRNA-25 in different malignant tumors in Chinese population.Methods:The research on the diagnostic value of miRNA-25 in China national knowledge internet (CKNI), VIP, Wanfang, PubMed and EMBase was searched. The publication time was from the establishment of database to October 2019. After the data was extracted, the Meta.DiSc1.4 software was used for preliminary statistical analysis. The Review Manager 5.3's QUADAS-2 tool was used for quality control of the incoming literature. The STATA 15.0 software was used to analyze whether there was publication bias.Results:A total of 10 articles were included in the study, including 792 cases in the case group and 715 cases in the control group. The combined sensitivity, combined specificity, combined specificity, combined positive likehood ratio(PLR), negative likehood ratio (NLR) were 0.71(95% CI: 0.69-0.74), 0.84(95% CI: 0.81-0.86), 4.29(95% CI: 3.39-5.42), 0.35(95% CI: 0.31-0.40), respectively. Diagnostic odds rate (DOR) was 13.09(95% CI: 9.64-17.78), and the area under curve (AUC) was 0.80(95% CI: 0.77-0.84). Subgroup analysis showed that the diagnostic value of miRNA-25 for different malignant tumors suggested that the lung cancer group had the highest diagnostic value and specificity (DOR=16.418, SPE=0.863). Funnel plot indicated that no significant publication bias was found ( P=0.21). Conclusions:miRNA-25 is highly sensitive and specific to different malignancies, especially lung cancer, and can be used as a potential screening biomarker to assist diagnosis.
